Triple

T16952555
Position Surface form Disambiguated ID Type / Status
Subject Ambien E411218 entity
Predicate brandVariant P64697 FINISHED
Object Ambien CR E411218 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Ambien CR | Statement: [Ambien, brandVariant, Ambien CR]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Ambien CR
Context triple: [Ambien, brandVariant, Ambien CR]
  • A. Ambien chosen
    Ambien is a widely prescribed sedative-hypnotic medication (generic name zolpidem) used short-term to treat insomnia by helping people fall asleep more quickly.
  • B. Daypro
    Daypro is a prescription nonsteroidal anti-inflammatory drug (NSAID) containing oxaprozin, used to relieve pain and inflammation in conditions such as osteoarthritis and rheumatoid arthritis.
  • C. Kalydeco
    Kalydeco is a prescription medication used to treat certain forms of cystic fibrosis by improving the function of defective CFTR proteins.
  • D. Andexxa
    Andexxa is a recombinant modified human factor Xa protein used as a reversal agent to counteract the anticoagulant effects of factor Xa inhibitors such as rivaroxaban and apixaban.
  • E. Acomplia
    Acomplia is the brand name for rimonabant, a cannabinoid receptor antagonist that was developed as an anti-obesity drug but withdrawn due to psychiatric side effects.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: brandVariant
Context triple: [Ambien, brandVariant, Ambien CR]
  • A. brandNameVariant
    Indicates that one brand name is an alternative or variant form of another brand name, such as a spelling, regional, or stylistic variation.
  • B. bodyVariant
    Indicates that one entity is an alternative physical form or version of another entity’s body.
  • C. brandAttribute
    Indicates that a specific attribute or characteristic is associated with, or describes, a particular brand.
  • D. brandLanguageVariant
    Indicates that one language variant of a brand is related to or derived from another language version of the same brand.
  • E. productVariant chosen
    Indicates that one entity is a specific variant or version of a more general product entity.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d886c9c9d481909afe222093641cae completed April 10, 2026, 5:12 a.m.
NER Named-entity recognition batch_69e3d0197f308190af7185fc9cc7a6e9 completed April 18, 2026, 6:40 p.m.
NED1 Entity disambiguation (via context triple) batch_6a00d46213b08190b33b48d12bc795d1 completed May 10, 2026, 6:54 p.m.
PD Predicate disambiguation batch_69e32b9aa8748190b248890aca86753d completed April 18, 2026, 6:58 a.m.
Created at: April 10, 2026, 5:31 a.m.